BioSpace News Archive

Investment will bring Canada’s first centre of manufacturing excellence of nanomedicine-based RNA vaccines, gene therapies and cell therapies. At project completion early in 2023, the approximately 40,000 square foot leased bio-manufacturing facility will have multiple GMP suites with manufacturing lines for the end-to-end manufacturing of genetic medicines.

Texas is among an initial 11 state rollout and part of the company’s larger plan to expand access to COVID-19 vaccines at CVS Pharmacy locations across the country

Rhode Island is among an initial 11 state rollout and part of the company’s larger plan to expand access to COVID-19 vaccines at CVS Pharmacy locations across the country

South Carolina is among an initial 11 state rollout and part of the company’s larger plan to expand access to COVID-19 vaccines at CVS Pharmacy locations across the country

Harvey H. McKenzie is a (Life Member) Chartered Professional Accountant (CPA-CA), granted by the Chartered Professional Accountants of Ontario will be an advisory consultant for CVR Medical and has agreed to a nomination to the Board of Directors.

COVAXX is developing the world’s first multitope protein/peptide-based vaccine to fight COVID-19, using its high precision, commercially proven and scalable vaccine platform.

CVS Health Corporation will hold a conference call with analysts and investors on Tuesday, February 16, 2021, at 8:00 a.m. to discuss its financial results for the fourth quarter of 2020.

Net proceeds will help support planning of clinical trials for JAN101, the company’s lead drug candidate

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced memorandum of understanding with the Canadian government to produce NVX-CoV2373, the Company’s protein-based vaccine candidate against COVID-19 in Canada.

HistoSonics, developer of a non-invasive platform and novel sonic beam therapy, announced today the treatment of the first patient in the #HOPE4LIVER US Study.